Author: Kathrynne HoldenPublished: 26 January 2017
Prep: -Cook: -Serves: -
In her latest nutrition article, former National Parkinson Foundation dietician Kathrynne Holden, explains the benefits of vitamin B3 – also known as niacin – for people with young-onset Parkinson’s
Vitamin B3, or niacin, is one of the vitamins needed for human life. While it is necessary for everyone, it may have added value for people with inherited Parkinson’s disease.
In a recent research study from the University of Leicester, scientists examined the effect of niacin-rich foods on fruit flies. The flies had a genetic mutation similar to the one in people with hereditary Parkinson’s disease. They learned that the high-niacin food prevented the degeneration of neurons in the brains of the flies.
What does this mean for people with Parkinson’s disease?
We can’t assume that an animal study will apply to humans. About 75% of the DNA in fruit flies is the same as human DNA, so although flies are good research subjects, the study results are not conclusive.
However, it is still possible that niacin-rich foods could benefit people with Parkinson’s disease. As niacin is already being used in cancer studies, and in treating strokes, we can trust that increasing high-niacin foods in our diet will be safe, and may be therapeutic. It is important to note that the research indicates that natural, food-based sources of niacin/vitamin B3 are preferable, rather than supplement tablets.
How much niacin/vitamin B3 do we need daily?
The recommended daily amount (RDA) of vitamin B3 for adults is 16mg for men and 14mg for women. There is no risk of excess or toxicity from foods. However, with use of supplement tablets there is an upper limit of 35mg per day for adults. Very high doses of supplements can cause a burning sensation in the skin of the face and chest, and can increase histamine in people with allergies. Another factor to be aware of is that some people with Parkinson’s disease have orthostatic hypotension (low blood pressure) and vitamin B3 supplements can cause a dangerous drop in blood pressure.
Which foods are high in vitamin B3?
High-protein foods are the richest in vitamin B3. We must consider that people using levodopa may be sensitive to protein, and, if so, will need to carefully time medications and meals, so that the levodopa is absorbed into the bloodstream ahead of protein in the meal.
By combining servings of high-protein foods with grains, vegetables, pulses and fruits you can be certain to get plenty of vitamin B3 in your daily menu. Below is a one-day meal plan that’s high in vitamin B3.
Morning meal 1 cup cooked barley cereal with milk or milk alternative 3.2mg
1 slice whole wheat bread, toasted with butter 1.3mg
1 banana 0.67mg
Juice, milk, coffee or tea as desired
Midday meal Tuna sandwich
(with canned tuna and two slices whole wheat bread 9.6mg
Coleslaw or lettuce salad
Beverage of choice
The day’s menu exceeds the RDA for both men and women, yet is well below the upper limit of 35mg. Whether you are living with Parkinson’s or not, this is a healthy day’s menu, with a variety of foods, and ample vitamin B3.
‘Shakshuka’ is a dish of eggs poached in a sauce of tomatoes, chili peppers and onions
Registration for the Team Fox summer 2016 cycle series now open
2 days ago
Chemical used in dry cleaning may be associated with Parkinson’s disease
The chemical trichloroethylene (TCE) has been used across a number of industries: to decaffeinate coffee, degrease metal parts, remove stains and dry-clean clothing. It’s currently banned in the European Union and the US states New York and Minnesota, except for authorised industrial uses. Now, scientists led by Dr Ray Dorsey in the US have conducted new research claiming that TCE could be linked to an increased risk of Parkinson’s. Published in the ‘Journal of Parkinson’s Disease’, the study investigated case studies of seven people who were exposed to TCE prior to a Parkinson’s diagnosis – including basketball legend Brian Grant. The researchers “postulate that this ubiquitous chemical is contributing to the global rise of Parkinson’s and that TCE is one of its invisible and highly preventable causes”. They called for the cleaning of TCE-contaminated sites and for indoor air exposure to be diminished – as well as for further studies to be…
Could certain cancers be linked to Parkinson’s disease?
Previous research has suggested that people with Parkinson’s may generally be less likely to develop most cancers. However, a new international study has found a potential genetic link between certain types of cancer and the condition. The team analysed genetic data from genome-wide association studies – a research approach that aims to identify gene variations associated with disease risk – to recognise common genetic risk factors between cancer and Parkinson’s. The findings uncovered a genetic link between the condition and both prostate cancer and melanoma. Meanwhile, the sum of various gene variants (otherwise known as the polygenic risk score) that contribute to Parkinson’s was significantly associated with a higher risk of breast cancer. “Our results suggest the importance of shared genetic variants between Parkinson’s and some cancers,” the researchers concluded in the study, which was published in the medical journal ‘Movement Disorders’. They highlighted the need for further studies to…
Investigational Parkinson’s disease dementia therapy fails in clinical trial
Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…